iXensor, the pioneer of mobile health, is set to launch its end-to-end digital COVID-19 rapid antigen test solution that digitizes the entire user journey from screening, reporting to access control to combat outbreaks. The clinical performance evaluation has demonstrated superior accuracy of the PixoTest® POCT COVID-19 Antigen Test. The test…
While the current COVID-19 pandemic keeps impacting us globally, this will hardly have been the last pandemic of our times. What can we do to be better prepared or even prevent it from happening, though? Join our CEO, Dr. Carson Chen, as he discusses this timely topic together with other…
Rising burden of non-communicable diseases Similar to other developing countries, diabetes and other non-communicable diseases (NCDs) have become a threat to Kenya a decade ago. Particularly, diabetes often results in life-long, irreversible complications that are usually very costly to treat. It was reported that the prevalence of diabetes in Kenya…
Business Challenge In the face of COVID-19, health care systems worldwide have been prompted to spare non-critical hospital visits among chronic disease patients. As a result, chronic disease patients face a very unique challenge, as their health condition demands long-term monitoring, active alerting and near-by consultancy with comprehensive records of…
While most major economies continue to strive against rising infections and deaths caused by the novel coronavirus, Taiwan has set itself up for an economic revival due to its successful pandemic control measures. The CEO of iXensor,Carson Chen, invited by the Society for Promotion of East West Knowledge Transfer, gave…
iXensor, the pioneer of mobile health, infuses its corporate DNA of digital savviness into its upcoming product launch in January 2021. The PixoTest® COVID-19 Antigen Test, together with the PixoTest® POCT Analyzer, can yield positive results objectively in as short as 5 minutes through computer-aided analysis, minimizing the chances of…
iXensor, the pioneer of mobile health, infuses its corporate DNA of digital savviness into its upcoming product launch in January 2021. The PixoTest® COVID-19 Antigen Test, together with the PixoTest® POCT Analyzer, can yield positive results objectively in as short as 5 minutes through computer-aided analysis, minimizing the chances of misinterpretation by…
iXensor attended Medica 2020 in October and presented the PixoTech technology as well as its new application of smart COVID-19 management. “Health & Care Management” from Germany reported it as “Pioneering medical technology from Taiwan.” Read the full article here: https://www.hcm-magazin.de/zukunftsweisende-medizintechnik-aus-taiwan/150/25761/408612
iXensor announced today that, effective December 1st, it has become a resident of Johnson & Johnson Innovation – JLABS @ Shanghai. This is an important step toward further accelerating its PixoTech platform development and smartphone-based testing applications for new disease areas, leveraging JLABS’ global network and resources. Johnson Innovation…
TAIPEI, TAIWAN / SINGAPORE – November 25th, 2020 – iXensor Co., Ltd. (6734.TWO) Backed by two pharmaceutical giants Roche, Sanofi and organized by Plug and Play, the Startup Creasphere Program selected iXensor to join its three-month digital health accelerator program, which aimed for transforming healthcare together. In this first…
